Symptoms of overdose and/or acute systemic toxicity involves central nervous system toxicity that presents with symptoms of increasing severity L5930. Patients may present initially with circumoral paraesthesia, numbness of the tongue, light-headedness, hyperacusis, and tinnitus L5930. Visual disturbance and muscular tremors or muscle twitching are more serious and precede the onset of generalized convulsions L5930. These signs must not be mistaken for neurotic behavior L5930. Unconsciousness and grand mal convulsions may follow, which may last from a few seconds to several minutes L5930. Hypoxia and hypercapnia occur rapidly following convulsions due to increased muscular activity, together with the interference with normal respiration and loss of the airway L5930. In severe cases, apnoea may occur. Acidosis increases the toxic effects of local anesthetics L5930. Effects on the cardiovascular system may be seen in severe cases L5930. Hypotension, bradycardia, arrhythmia and cardiac arrest may occur as a result of high systemic concentrations, with potentially fatal outcome L5930.
Pregnancy Category B has been established for the use of lidocaine in pregnancy, although there are no formal, adequate, and well-controlled studies in pregnant women F4349. General consideration should be given to this fact before administering lidocaine to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place F4349. Ultimately, although animal studies have revealed no evidence of harm to the fetus, lidocaine should not be administered during early pregnancy unless the benefits are considered to outweigh the risks L5930. Lidocaine readily crosses the placental barrier after epidural or intravenous administration to the mother L5930. The ratio of umbilical to maternal venous concentration is 0.5 to 0.6 L5930. The fetus appears to be capable of metabolizing lidocaine at term L5930. The elimination half-life in the newborn of the drug received in utero is about three hours, compared with 100 minutes in the adult L5930. Elevated lidocaine levels may persist in the newborn for at least 48 hours after delivery L5930. Fetal bradycardia or tachycardia, neonatal bradycardia, hypotonia or respiratory depression may occur L5930.
Local anesthetics rapidly cross the placenta and when used for epidural, paracervical, pudendal or caudal block anesthesia, can cause varying degrees of maternal, fetal and neonatal toxicity F4349. The potential for toxicity depends upon the procedure performed, the type and amount of drug used, and the technique of drug administration F4349. Adverse reactions in the parturient, fetus and neonate involve alterations of the central nervous system, peripheral vascular tone, and cardiac function F4349.
Maternal hypotension has resulted from regional anesthesia F4349. Local anesthetics produce vasodilation by blocking sympathetic nerves F4349. Elevating the patient’s legs and positioning her on her left side will help prevent decreases in blood pressure F4349. The fetal heart rate also should be monitored continuously, and electronic fetal monitoring is highly advisable F4349.
Epidural, spinal, paracervical, or pudendal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts F4349. In one study, paracervical block anesthesia was associated with a decrease in the mean duration of first stage labor and facilitation of cervical dilation F4349. However, spinal and epidural anesthesia have also been reported to prolong the second stage of labor by removing the parturient’s reflex urge to bear down or by interfering with motor function F4349. The use of obstetrical anesthesia may increase the need for forceps assistance F4349.
The use of some local anesthetic drug products during labor and delivery may be followed by diminished muscle strength and tone for the first day or two of life F4349. The long-term significance of these observations is unknown F4349. Fetal bradycardia may occur in 20 to 30 percent of patients receiving paracervical nerve block anesthesia with the amide-type local anesthetics and may be associated with fetal acidosis F4349. Fetal heart rate should always be monitored during paracervical anesthesia F4349. The physician should weigh the possible advantages against risks when considering a paracervical block in prematurity, toxemia of pregnancy, and fetal distress F4349. Careful adherence to the recommended dosage is of the utmost importance in obstetrical paracervical block F4349. Failure to achieve adequate analgesia with recommended doses should arouse suspicion of intravascular or fetal intracranial injection F4349. Cases compatible with unintended fetal intracranial injection of local anesthetic solution have been reported following intended paracervical or pudendal block or both. Babies so affected present with unexplained neonatal depression at birth, which correlates with high local anesthetic serum levels, and often manifest seizures within six hours F4349. Prompt use of supportive measures combined with forced urinary excretion of the local anesthetic has been used successfully to manage this complication F4349.
It is not known whether this drug is excreted in human milk F4349. Because many drugs are excreted in human milk, caution should be exercised when lidocaine is administered to a nursing woman F4349.
Dosages in children should be reduced, commensurate with age, body weight and physical condition F4349.
The oral LD 50 of lidocaine HCl in non-fasted female rats is 459 (346-773) mg/kg (as the salt) and 214 (159-324) mg/kg (as the salt) in fasted female rats F4349.
Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication T583. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures F4349, L5930, L5948. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations F4349, L5930, L5948. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others F4349, L5930, L5948. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent L5930, L5948, F4468. Nevertheless, lidocaine's local anesthetic action sees its use in many medical situations or circumstances that may benefit from its action, including the treatment of premature ejaculation A177625.
Regardless, lidocaine is currently available as a relatively non-expensive generic medication that is written for in millions of prescriptions internationally on a yearly basis. It is even included in the World Health Organization's List of Essential Medicines L6055.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Deferasirox | The serum concentration of Lidocaine can be increased when it is combined with Deferasirox. |
| Peginterferon alfa-2b | The serum concentration of Lidocaine can be increased when it is combined with Peginterferon alfa-2b. |
| Leflunomide | The serum concentration of Lidocaine can be decreased when it is combined with Leflunomide. |
| Teriflunomide | The serum concentration of Lidocaine can be decreased when it is combined with Teriflunomide. |
| Buprenorphine | Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Lidocaine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Lidocaine. |
| Hydrocodone | Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine. |
| Magnesium sulfate | The therapeutic efficacy of Lidocaine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Lidocaine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lidocaine. |
| Mirtazapine | Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Lidocaine. |
| Orphenadrine | Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Lidocaine. |
| Pramipexole | Lidocaine may increase the sedative activities of Pramipexole. |
| Rotigotine | Lidocaine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Lidocaine. |
| Sodium oxybate | Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lidocaine. |
| Thalidomide | Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Amiodarone | The risk or severity of generalized seizure and bradycardia can be increased when Amiodarone is combined with Lidocaine. |
| Hyaluronidase (ovine) | Hyaluronidase (ovine) can cause an increase in the absorption of Lidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase (human recombinant) | Hyaluronidase (human recombinant) can cause an increase in the absorption of Lidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase | Hyaluronidase can cause an increase in the absorption of Lidocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Zolmitriptan | The metabolism of Zolmitriptan can be decreased when combined with Lidocaine. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Lidocaine. |
| Atomoxetine | The metabolism of Atomoxetine can be decreased when combined with Lidocaine. |
| Agomelatine | The serum concentration of Agomelatine can be increased when it is combined with Lidocaine. |
| Pirfenidone | The metabolism of Pirfenidone can be decreased when combined with Lidocaine. |
| Tizanidine | The serum concentration of Tizanidine can be increased when it is combined with Lidocaine. |
| Mirabegron | The serum concentration of Lidocaine can be increased when it is combined with Mirabegron. |
| Abiraterone | The serum concentration of Lidocaine can be increased when it is combined with Abiraterone. |
| Cyproterone acetate | The metabolism of Lidocaine can be increased when combined with Cyproterone acetate. |
| Ethanol | Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine. |
| Desvenlafaxine | The serum concentration of Lidocaine can be increased when it is combined with Desvenlafaxine. |
| Sibutramine | The risk or severity of adverse effects can be increased when Lidocaine is combined with Sibutramine. |
| Zimelidine | The risk or severity of adverse effects can be increased when Lidocaine is combined with Zimelidine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Lidocaine is combined with Milnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Lidocaine is combined with Indalpine. |
| Alaproclate | The risk or severity of adverse effects can be increased when Lidocaine is combined with Alaproclate. |
| Esmolol | The serum concentration of Lidocaine can be increased when it is combined with Esmolol. |
| Betaxolol | The serum concentration of Lidocaine can be increased when it is combined with Betaxolol. |
| Metoprolol | The serum concentration of Lidocaine can be increased when it is combined with Metoprolol. |
| Atenolol | The serum concentration of Lidocaine can be increased when it is combined with Atenolol. |
| Timolol | The serum concentration of Lidocaine can be increased when it is combined with Timolol. |
| Sotalol | The serum concentration of Lidocaine can be increased when it is combined with Sotalol. |
| Labetalol | The serum concentration of Lidocaine can be increased when it is combined with Labetalol. |
| Bisoprolol | The serum concentration of Lidocaine can be increased when it is combined with Bisoprolol. |
| Alprenolol | The serum concentration of Lidocaine can be increased when it is combined with Alprenolol. |
| Pindolol | The serum concentration of Lidocaine can be increased when it is combined with Pindolol. |
| Carvedilol | The serum concentration of Lidocaine can be increased when it is combined with Carvedilol. |
| Propafenone | The serum concentration of Lidocaine can be increased when it is combined with Propafenone. |
| Acebutolol | The serum concentration of Lidocaine can be increased when it is combined with Acebutolol. |
| Nadolol | The serum concentration of Lidocaine can be increased when it is combined with Nadolol. |
| Bevantolol | The serum concentration of Lidocaine can be increased when it is combined with Bevantolol. |
| Practolol | The serum concentration of Lidocaine can be increased when it is combined with Practolol. |
| Penbutolol | The serum concentration of Lidocaine can be increased when it is combined with Penbutolol. |
| Oxprenolol | The serum concentration of Lidocaine can be increased when it is combined with Oxprenolol. |
| Dexpropranolol | The serum concentration of Lidocaine can be increased when it is combined with Dexpropranolol. |
| Celiprolol | The serum concentration of Lidocaine can be increased when it is combined with Celiprolol. |
| Nebivolol | The serum concentration of Lidocaine can be increased when it is combined with Nebivolol. |
| Bufuralol | The serum concentration of Lidocaine can be increased when it is combined with Bufuralol. |
| Bopindolol | The serum concentration of Lidocaine can be increased when it is combined with Bopindolol. |
| Bupranolol | The serum concentration of Lidocaine can be increased when it is combined with Bupranolol. |
| Indenolol | The serum concentration of Lidocaine can be increased when it is combined with Indenolol. |
| Arotinolol | The serum concentration of Lidocaine can be increased when it is combined with Arotinolol. |
| Levobetaxolol | The serum concentration of Lidocaine can be increased when it is combined with Levobetaxolol. |
| Talinolol | The serum concentration of Lidocaine can be increased when it is combined with Talinolol. |
| Anisodamine | The serum concentration of Lidocaine can be increased when it is combined with Anisodamine. |
| Bucindolol | The serum concentration of Lidocaine can be increased when it is combined with Bucindolol. |
| Esatenolol | The serum concentration of Lidocaine can be increased when it is combined with Esatenolol. |
| Cloranolol | The serum concentration of Lidocaine can be increased when it is combined with Cloranolol. |
| Mepindolol | The serum concentration of Lidocaine can be increased when it is combined with Mepindolol. |
| Epanolol | The serum concentration of Lidocaine can be increased when it is combined with Epanolol. |
| Tertatolol | The serum concentration of Lidocaine can be increased when it is combined with Tertatolol. |
| Landiolol | The serum concentration of Lidocaine can be increased when it is combined with Landiolol. |
| Dapsone | The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Lidocaine. |
| Ibutilide | Lidocaine may increase the arrhythmogenic activities of Ibutilide. |
| Hyoscyamine | Lidocaine may increase the arrhythmogenic activities of Hyoscyamine. |
| Acetyldigitoxin | Lidocaine may increase the arrhythmogenic activities of Acetyldigitoxin. |
| Carteolol | Lidocaine may increase the arrhythmogenic activities of Carteolol. |
| Atropine | Lidocaine may increase the arrhythmogenic activities of Atropine. |
| Adenosine | Lidocaine may increase the arrhythmogenic activities of Adenosine. |
| Moricizine | Lidocaine may increase the arrhythmogenic activities of Moricizine. |
| Levosimendan | Lidocaine may increase the arrhythmogenic activities of Levosimendan. |
| Deslanoside | Lidocaine may increase the arrhythmogenic activities of Deslanoside. |
| Bretylium | Lidocaine may increase the arrhythmogenic activities of Bretylium. |
| Metipranolol | Lidocaine may increase the arrhythmogenic activities of Metipranolol. |
| Ajmaline | Lidocaine may increase the arrhythmogenic activities of Ajmaline. |
| Azimilide | Lidocaine may increase the arrhythmogenic activities of Azimilide. |
| Tedisamil | Lidocaine may increase the arrhythmogenic activities of Tedisamil. |